Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Type 2 diabetes with glycosylated hemoglobin of greater than or equal to 9.0 to less than or equal to 11.0% at Screening.~* Documented hypertension.~* On a stable diet and exercise program in addition to metformin alone or combination of metformin and a sulfonylurea for a minimum of 8 weeks prior to screening.~* If receiving antihypertensive therapy, must be on no more than 3 agents and be on a stable regimen.~* Clinical laboratory evaluations (including clinical chemistry, hematology, and urinalysis) within the reference range unless the results are deemed not clinically significant for inclusion into this study by the investigator.~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~Exclusion Criteria~* Type 1 diabetes mellitus.~* Diastolic blood pressure greater than 104 mm Hg at randomization visit.~* Currently taking an angiotensin II-receptor blocker.~* Unstable angina or heart failure of any etiology with New York Heart Association functional class III or IV.~* History of myocardial infarction, cerebrovascular accident (stroke), percutaneous coronary intervention, coronary artery bypass graft or transient ischemic attack within the previous six months.~* Clinically significant cardiac conduction defects.~* Secondary hypertension of any etiology.~* Body mass index greater than 45 kg/m2~* Has significant renal dysfunction.~* History of drug abuse or a history of alcohol abuse within the past 2 years.~* Previous history of cancer, other than basal cell carcinoma or stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to the first dose of study drug.~* Alanine transaminase or aspartate transaminase level of greater than 2.5 times the upper limit of normal, active liver disease, or jaundice.~* Serum potassium greater than the upper limit of normal.~* Currently participating in another investigational study or has participated in an investigational study within 30 days prior to Randomization.~* Any other serious disease or condition that would compromise subject safety, might affect life expectancy, or make it difficult to successfully manage and follow the subject according to the protocol.~* Is hypersensitive to angiotensin II receptor blockers.~* Is hypersensitive to thiazolidinediones.~* Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:~  * any anti-diabetic agent (including thiazolidinediones and/or insulin) except for metformin or a combination of metformin and a sulfonylurea~ * niacin more than 200mg per day~ * tricyclic antidepressants or phenothiazines~ * Angiotensin II receptor blockers~ * Thiazolidinediones~ * Insulin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pioglitazone 45 mg/Azilsartan 20 mg QD (Type: EXPERIMENTAL): None
- Pioglitazone 45 mg/Azilsartan 40 mg QD (Type: EXPERIMENTAL): None
- Pioglitazone 45 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues